Clinical Trials Logo

Mixed Tumor, Mullerian clinical trials

View clinical trials related to Mixed Tumor, Mullerian.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04513665 Completed - Endometrial Cancer Clinical Trials

ZW25 in Women With Endometrial Cancers

Start date: August 12, 2020
Phase: Phase 2
Study type: Interventional

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

NCT ID: NCT03694262 Completed - Endometrial Cancer Clinical Trials

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

EndoBARR
Start date: July 19, 2019
Phase: Phase 2
Study type: Interventional

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.

NCT ID: NCT03395080 Completed - Ovarian Cancer Clinical Trials

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma

P204
Start date: March 5, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma

NCT ID: NCT03015129 Completed - Endometrial Cancer Clinical Trials

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Start date: January 2017
Phase: Phase 2
Study type: Interventional

This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer. Radiologic tumor assessment will be repeated every 8 weeks +/- 7 days for the first 48 weeks and then every 12 weeks +/- 7 days until PD. For patients who remain progression free 2 years post completion of protocol directed treatment, every 6 months +/- 1 month. irRECIST assessments will only be completed for patients continuing treatment beyond PD.

NCT ID: NCT02993705 Completed - Clinical trials for Carcinosarcoma, Ovarian

Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)

MITO 26
Start date: February 22, 2017
Phase: Phase 2
Study type: Interventional

Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.

NCT ID: NCT02983279 Completed - Breast Carcinoma Clinical Trials

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

Start date: September 20, 2016
Phase: N/A
Study type: Interventional

The purpose of this trial is to determine that sort term calorie restriction will affect tumor biology in biopsy proven breast, endometrial or prostate cancers, which will positively impact biomarkers including miR-21, an onco-miR known to impact cancer outcomes.

NCT ID: NCT01991808 Completed - Clinical trials for Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus

Suitability of DCE-MRI for Detection of Vascular Changes After VBT

Start date: October 2013
Phase: N/A
Study type: Interventional

This is a pilot study of DCE MR imaging to detect vascular changes in the vagina during and after radiotherapy n patients receiving adjuvant brachytherapyfor cervical or endometrial cancer.

NCT ID: NCT01247571 Completed - Clinical trials for Uterine Carcinosarcoma

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: January 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with uterine cancer that has come back or has not responded to treatment. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of uterine cancer by blocking blood flow to the tumor.

NCT ID: NCT01168232 Completed - Clinical trials for Uterine Carcinosarcoma

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

Start date: September 7, 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well ixabepilone works in treating patients with persistent or recurrent uterine cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.

NCT ID: NCT01080521 Completed - Clinical trials for Ovarian Endometrioid Adenocarcinoma

Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Start date: April 2010
Phase:
Study type: Observational

This clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy. Learning about the effects of chemotherapy on brain function may help doctors plan cancer treatments.